Huizhou He

Huizhou He

Auto-generated profile, based on publicly available information

Huizhou He

Department of Interventional Radiology The Affiliated Hospital of Guizhou Medical University Guiyang 550004 P. R. China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Advanced Functional Materials
Verified
Journal Article
Open access
ZCZhimei Cheng
Zhimei Cheng
SXShan Xu
Shan Xu
YLYi Lei
Yi Lei
HHHuizhou He
Huizhou He
RSRunbin Sun
Runbin Sun
SZShuai Zhang
Shuai Zhang
Transarterial chemoembolization (TACE) is considered the main treatment for intermediate and advanced liver cancer. Nevertheless, TACE may aggravate liver fibrosis in these patients, which could affect the therapeutic effect after TACE. Pirfenidone (PFD) exhibits significant antifibrotic effects in the liver, primarily via inhibition of hepatic stellate cells (HSCs) activation. However, owing to the high dose required for effective treatment, oral administration of PFD is associated with several side effects. This study introduces an oral folic acid (FA)‐modified protein‐polysaccharide PFD nanoemulsion designed to treat post‐TACE liver fibrosis via liver targeting. This novel PFD oral nanoemulsion withstands gastrointestinal digestion and ensures the gastrointestinal stability of PFD. Furthermore, this nanoemulsion improves the intestinal permeability and antifibrotic efficacy of PFD at a lower dose via folate receptors expressed on both intestinal epithelial cells and activated HSCs. In conclusion, this FA‐modified protein‐polysaccharide nanoemulsion presents a promising approach for oral PFD delivery to effectively ameliorate fibrosis after TACE for liver cancer.